Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Round Of Drug Maker Consolidation Expected In Japan

This article was originally published in PharmAsia News

Executive Summary

Japan's drug-making industry anticipates a new spurt of consolidation moves as previous capital investments cause companies charge off increasing amounts of depreciation. The generics part of the industry in Japan is estimated to be using only a little more than half its production capacity as a result of firms expanding capacity ahead of expected market growth. That situation is expected to make small and midsize firms exposed as targets for acquisition, particularly in the eyes of Indian drug makers. But large Japanese firms also are beginning to buy their smaller cousins. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts